Earnings Summary

Rocket Pharmaceuticals Inc’s revenue jumped +Inf% since last year same period to $10.31Mn in the Q4 2023. On a quarterly growth basis, Rocket Pharmaceuticals Inc has generated +Inf% jump in its revenue since last 3-months.

Rocket Pharmaceuticals Inc’s net profit jumped 7.31% since last year same period to $-59.66Mn in the Q4 2023. On a quarterly growth basis, Rocket Pharmaceuticals Inc has generated 3.62% jump in its net profits since last 3-months.

Rocket Pharmaceuticals Inc’s net profit margin jumped NaN% since last year same period to -578.55% in the Q4 2023. On a quarterly growth basis, Rocket Pharmaceuticals Inc has generated NaN% jump in its net profit margins since last 3-months.

Rocket Pharmaceuticals Inc’s earning per share (EPS) estimates for the current quarter stand at -0.68 - a 13.92% jump from last quarter’s estimates.

Rocket Pharmaceuticals Inc’s earning per share (EPS) estimates for the current year stand at -0.68.

Rocket Pharmaceuticals Inc’s earning per share (EPS) jumped 30.43% since last year same period to -0.64 in the Q4 2023. This indicates that the Rocket Pharmaceuticals Inc has generated 30.43% annual rate of jump in its earning per share (EPS) in the last 4 quarters.

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Rocket Pharmaceuticals Inc’s return on assets (ROA) stands at -0.29.

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Rocket Pharmaceuticals Inc’s return on equity (ROE) stands at -0.5.